Harry J. Leonhardt

SVP, Gen Counsel & Corp Sec, Senomyx.

Companies

Poseida Therapeutics, Inc.GC & Chief Compliance Officer Sep 22, 2020 to Jan 8, 2025¹
Halozyme TherapeuticsSVP, GC and CCO Apr 15, 2015 to Apr 15, 2019²
Amylin PharmaceuticalsVP Legal & Corporate Secretary Jun 9, 2010 to Feb 24, 2012³
SenomyxSVP, Gen Counsel & Corp Sec Feb 3, 2006 to Sep 4, 2007⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Poseida Therapeutics, Inc.0 shares⁵Jan 8, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

Jan 8, 2025U 223,640 shares of Poseida Therapeutics, Inc.⁵
Mar 1, 2024Shares withheld for tax 16,306 shares at $4.13 of Poseida Therapeutics, Inc.⁶
Mar 1, 2024Granted 80,743 shares of Poseida Therapeutics, Inc.⁶
Mar 1, 2023Shares withheld for tax 4,323 shares at $5.35 of Poseida Therapeutics, Inc.⁷
Mar 1, 2023Granted 92,772 shares of Poseida Therapeutics, Inc.⁷
Mar 1, 2022Granted 50,000 shares of Poseida Therapeutics, Inc.⁸

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARPoseida Therapeutics, Inc., GC & Chief Compliance Officer
2
SEC EDGARHalozyme Therapeutics, SVP, GC and CCO
3
SEC EDGARAmylin Pharmaceuticals, VP Legal & Corporate Secretary
4
SEC EDGARSenomyx, SVP, Gen Counsel & Corp Sec
5
SEC EDGARPoseida Therapeutics, Inc. shares after the filing of Jan 8, 2025
6
SEC EDGARForm 4 filed Mar 4, 2024
7
SEC EDGARForm 4 filed Mar 2, 2023
8
SEC EDGARForm 4 filed Mar 1, 2022